12 Key Performance Data Summary Performance Indicator Measure 2020/21 2021/22 2022/23 More in 22/23 Annual Report (page reference) Economic Contribution Operating revenue US$ million 10,310¶ 10,562¶ 13,310¶^ 21 Net profit US$ million 2,375¶ 2,255¶ 2,194¶^ Economic value generated US$ million 10,314† 10,570† 13,348†^ 53 Economic value distributed US$ million 9,959† 9,866† 13,209†^ New plasma centres Number 25 27 12 20 Sustainable Workforce Our People Total headcount Number 25,415 30,398† 32,065†^ 40 Total Board female Percentage 43 44† 44†^ Total workforce female Percentage 57 61† 59†^ Total people managers female Percentage 44 46† 45†^ Total senior executives female Percentage 30 31† 32†^ Total Recordable Injury Frequency Rate (TRIFR)‡ Per million hours worked for Non-CSL Plasma sites 1.9† 1.4† 0.94†^ 45 Per million hours worked for CSL Plasma 11.2† 10.7† 12.1† Fatalities (including contingent workers) Number 0 0† 0†^ Employee engagement Percentage 73.7† 77.9† 76.2†^ 44 ESG employee engagement NA 78.2† 76.2†^ 44 Social Innovation R&D investment US$ million 1,001† 1,156† 1,232†^ 20 Clinical trials in operation Number 43 58 60 39 Safety and Quality Regulatory audits of manufacturing facilities and plasma collection centres Number 365† 406† 475†^ 53 Safety related recalls of finished product†† Number 3† 0† 3†^ Pharmacovigilance audits Number 64 69 94 53 Community Total contribution US$ million 55.2# 50.0 42.6 58 Product access support (subset of total community contribution) US$ million 20.1#† 17.8† 13.7† 55 Plasma donors willing to donate again Percentage 99† 95^^ 94† 57 Environment Absolutes§ Energy consumption Petajoules 3.73 3.92 4.21†^ 47 Scope 1 & 2 greenhouse gas emissions Metric kilotonnes 326 347 336†^ Water consumption Gigalitres 4.44 4.67 4.86 Waste Metric kilotonnes 59.02 55.54 72.00 Waste recycling rate Percentage 40 38 44 † Data for nominated period has received limited assurance by Ernst & Young. ¶ Operating Revenue and Net Profit extracted from the audited financial statements. †† Safety related recalls relate to finished products which must be retrieved due to a known or possible adverse or health related impact on a patient. These include safety related recalls which are classified as a class 1 and 2 recall by the regulator. § See page 47 for more on reporting boundary. # Accounting practices for CSL Seqirus Australia product donations changed in 2020/21 to account for indirect and direct costs (versus direct only for prior years). ^ Includes CSL Vifor data. TRIFR and environmental metrics includes CSL Vifor data for Switzerland only. ^^ Data for nominated period has received limited assurance by Ernst & Young. Data collectionmethod changed for the reporting period, see section 9, Plasma donors. Reporting Boundary Our disclosure covers the businesses and operations over which we exercise direct control and incorporates CSL Limited, CSL Behring (including CSL Plasma), CSL Seqirus, CSL Vifor and global research and development (R&D). This includes our nine manufacturing facilities in Australia, China, Europe, the UK and the United States as well as R&D, sales and marketing, distribution and administration activities co-located with these facilities. Other R&D activities, sales and marketing, distribution and administrative activities occurring away from our manufacturing facilities are also covered by this report, including the full network of donation centres, laboratories and administration offices operated by CSL Plasma. Where indicated, CSL Vifor, which was acquired in August 2022, has been excluded in some metrics as integration/harmonisation activities continue. CSL Limited Annual Report 2022/23 73
RkJQdWJsaXNoZXIy MjE2NDg3